share_log

藥明合聯：股東週年大會通知

WUXI XDC: NOTICE OF ANNUAL GENERAL MEETING

Hong Kong Stock Exchange ·  May 21 18:04
Summary by Futu AI
藥明合聯生物技術有限公司將於2024年6月12日舉行股東週年大會，地點為中國江蘇省無錫市。會議將審核及接納截至2023年12月31日止年度的經審核綜合財務報表、董事會報告及獨立核數師報告。此外，會上將重選李錦才博士、張靖偉先生及席曉捷先生為執行董事，並授權董事會釐定董事年度酬金。大會亦將續聘德勤會計師行為核數師並授權董事會釐定其酬金。股東將審議2024年股份計劃，包括授權上限及服務提供商分項上限，並授權董事會在適當時採取必要行動。另外，將討論授予董事發行及處理股份的一般授權，以及購回本公司股份的授權。所有決議案的資料詳情已載於2024年5月21日的通函中。
藥明合聯生物技術有限公司將於2024年6月12日舉行股東週年大會，地點為中國江蘇省無錫市。會議將審核及接納截至2023年12月31日止年度的經審核綜合財務報表、董事會報告及獨立核數師報告。此外，會上將重選李錦才博士、張靖偉先生及席曉捷先生為執行董事，並授權董事會釐定董事年度酬金。大會亦將續聘德勤會計師行為核數師並授權董事會釐定其酬金。股東將審議2024年股份計劃，包括授權上限及服務提供商分項上限，並授權董事會在適當時採取必要行動。另外，將討論授予董事發行及處理股份的一般授權，以及購回本公司股份的授權。所有決議案的資料詳情已載於2024年5月21日的通函中。
Pharmaceutical United Biotechnology Co., Ltd. will hold its Annual General Meeting on June 12, 2024 at Wuxi City, Jiangsu Province, China. The Conference will review and accept the Audited Consolidated Financial Statements, Board Reports and Independent Auditor's Reports for the year ended 31 December 2023. In addition, the meeting will re-elect Dr. Li Kam Chai, Mr. Zhang Jingwei and Mr. Shi Xiaojie as Executive Directors and authorize the Board of Directors to determine the annual remuneration of the Directors. The General Meeting will also renew the appointment of Dedicine Accountants as an acting auditor and authorize the Board of Directors to determine their remuneration. Shareholders will review the 2024 share plan, including the maximum license and service provider allowance, and authorize the Board of Directors to take appropriate action as appropriate. In addition, discussion will be given to the Director of the General Mandate to issue and process shares and the authorization to repurchase the Company's shares. Details of all resolutions are set out in the Circular dated 21 May 2024.
Pharmaceutical United Biotechnology Co., Ltd. will hold its Annual General Meeting on June 12, 2024 at Wuxi City, Jiangsu Province, China. The Conference will review and accept the Audited Consolidated Financial Statements, Board Reports and Independent Auditor's Reports for the year ended 31 December 2023. In addition, the meeting will re-elect Dr. Li Kam Chai, Mr. Zhang Jingwei and Mr. Shi Xiaojie as Executive Directors and authorize the Board of Directors to determine the annual remuneration of the Directors. The General Meeting will also renew the appointment of Dedicine Accountants as an acting auditor and authorize the Board of Directors to determine their remuneration. Shareholders will review the 2024 share plan, including the maximum license and service provider allowance, and authorize the Board of Directors to take appropriate action as appropriate. In addition, discussion will be given to the Director of the General Mandate to issue and process shares and the authorization to repurchase the Company's shares. Details of all resolutions are set out in the Circular dated 21 May 2024.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

The translation is provided by third-party software.


The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.